Frontage is a global CRO advancing drug discovery and development with a comprehensive portfolio of genomics services. We deliver accurate and in-depth analyses to move compounds through early discovery and preclinical studies and for translational and clinical programs.
Register to gain access to gated resources.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
Frontage has developed a next-generation sequencing (NGS)-based method to rapidly determine the genotype of 300+ genes involved in ADME, called the Frontage PGx NGS Test.
Frontage Genomics successfully completed the Sponsor's request to transfer a method developed on MiSeq to MiniSeq.